|
 |
RetisertThis page contains recent news articles, when available, and an overview of Retisert but does not offer medical advice. You should contact your physician with regard to any health issues or concerns....as the installment of a time-release drug delivery device, such as Retisert (fluocinolone intravitreal implant, Bausch & Lomb),â€? Dr. Foster said. ... OSN SuperSite IRW-Press: Psivida Limited: Psivida Announces Positive Results From The Two ... - Dec 24, 2009 ...pSivida also has two products approved by the Food and Drug Administration (FDA): Retisert® for the treatment of posterior uveitis and Vitrasert® for the ... OfficialWire (press release) PSIVIDA MELDET POSITIVE ERGEBNISSE DER BEIDEN PHASE-III-FAMEâ„¢-VERSUCHE VON ... - Dec 24, 2009 ...pSivida verfügt auch über zwei Produkte, die bereits von der Food and Drug Administration (FDA) genehmigt wurden: Retisert® zur Behandlung von Uveitis und ... Firmenpresse (Pressemitteilung) pSivida Ltd. Reports Operating Results (10-Q) - Nov 13, 2009 Retisert is FDA approved for the treatment of uveitis. Vitrasert is FDA approved for the treatment of AIDS-related CMV Retinitis. ... GuruFocus.com pSivida Corp. Reports Results for the First Quarter Ended September 30, 2009 - Nov 12, 2009 ...pSivida also has two products approved by the Food and Drug Administration (FDA): Retisert ® for the treatment of posterior uveitis and Vitrasert ® for the ... WELT ONLINE pSivida Corp. Announces First Quarter 2010 Financial Results Release Date and ... - Nov 5, 2009 ...pSivida also has two products approved by the Food and Drug Administration (FDA): Retisert ® for the treatment of uveitis and Vitrasert ® for the treatment ... WELT ONLINE IRW-PRESS: pSivida Limited: PSIVIDA CORP. MELDET VERÖFFENTLICHUNGSDATUM DER ... - Nov 5, 2009 ...pSivida verfügt auch über zwei Produkte, die bereits von der Food and Drug Administration (FDA) genehmigt wurden: Retisert® zur Behandlung von Uveitis und ... Märkische Allgemeine pSivida meldet Abschluss der BrachySilâ„¢-Dosisfindungsstudie bei ... - Oct 22, 2009 ...und mangelnde Rentabilität; keine Einkünfte aus Retisert; Beendigung von Lizenzvereinbarungen; Unfähigkeit, Registrierungsgebühren zu entrichten; ... pressnetwork (Pressemitteilung) Bausch & Lomb, Novartis to co-promote Retisert eye drug in the US - Feb 9, 2006 ZURICH (AFX) - Bausch & Lomb said it and Novartis AG unit Novartis Ophtalmics are to co-promote eye drug Retisert in the United States. ... Forbes FDA Approves Orphan Drug Retisert (Fluocinolone Acetonide Intravitreal... - Apr 11, 2005 ROCHESTER, NY -- April 11, 2005 -- Bausch & Lomb announced today that the US Food and Drug Administration has approved the single-indication orphan drug ... DG News Diabetic Macular Edema trial with Retisertâ„¢ — Positive Results for … - Feb 21, 2006 The study concluded that significantly more patients receiving a Retisertâ„¢ implant had improved visual acuity (of three or more lines on an eye chart) than ... Nano World News pSivida Release: Positive European trial results for Retisert(TM). - Apr 6, 2006 PERTH, Australia & BOSTON -- Global bio-nanotech company pSivida Limited (Nasdaq:PSDV)(ASX:PSD)(GER:PSI) today announced that global eye health company ... Free with registration - Business Wire - AccessMyLibrary.com Bausch & Lomb Ireland Withdraws Marketing Application for Retisert - Jul 25, 2007 The European Medicines Agency (EMEA) announced it was notified by Bausch & Lomb Ireland of the company's decision to withdraw the centralized marketing ... FDA news - FDA news (subscription) FDA approves Bausch & Lomb's Retisert orphan drug - Apr 16, 2005 April 17 — Washington, DC — Bausch & Lomb announced that the FDA has approved the single-indication orphan drug Retisert (fluocinolone acetonide ... Ophthalmology Times pSivida News: Retisertâ„¢ Slows Progression of Diabetic Retinopathy in ... - Apr 3, 2006 Bausch & Lomb, exclusive licensee of Retisertâ„¢ from pSivida conducted the studies in hospitals in the United States involving 277 patients. ... Nano World News Two-Year Data from Clinical Trial of Retisert Presented at ARVO. - May 3, 2005 FT. LAUDERDALE, Fla. -- Today at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), lead investigator Dr. Glenn J. Jaffe ... $4.95 - Business Wire - ECNext Retisert (Fluocinolone acetonide) Intravitreal Implant - Apr 8, 2005 Indication: Retisert (Fluocinolone acetonide) intravitreal implant is indicated for the treatment of chronic noninfectious uveitis affecting the posterior ... Medscape pSivida Announces Sale of American Depositary Shares and Warrants - Jul 2, 2007 ...pSivida has developed the only two FDA approved sustained release back of the eye treatments for chronic eye disease, Vitrasert® and Retisert®. ... Nanotechnology News - Nanotechnology News (press release) RETISERT Bausch & Lomb submitted for approval, USA (eye disease).( … - Jan 10, 2005 Bausch & Lomb announced on 14 December 2004 that the US FDA has accepted an NDA for its RETISERT implant for review. The NDA submission, which was completed ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones … - 244.003 Fluocinolone Acetonide Intravitreal Implant (Retisert) - Apr 2, 2008 244.003 Fluocinolone Acetonide Intravitreal Implant (Retisert) 8-1-07 Medicaid covers Retisert implantation for ages and indications approved by the FDA ... Pay-Per-View - Arkansas Regulations - Loislaw pSivida Corp: BrachySilâ„¢ Phase IIb Pancreatic Cancer Trials Commence - Jul 9, 2008 Retisert® is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the ... Bausch & Lomb owns the trademarks Vitrasert® and Retisert®. ... Medical News Today - Medical News Today (press release) pSivida Appoints Boston Based Chief Financial Officer and General … - May 23, 2006 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks; Vitrasert(R) and Retisert(TM). ... Free with registration - Business Wire - AccessMyLibrary.com pSivida Reports Retisertâ„¢ Approved for Full US Medicare Rebate - Oct 7, 2005 ...pSivida announced that the Centers for Medicare & Medicaid Services in the United States has designated the single-indication orphan drug Retisertâ„¢ as ... Nano World News Mississippi's First Procedure with Retisertâ„¢ May Help Save Eye Sight ... - Jan 19, 2006 Jackson, MS (PRWEB) January 19, 2006 -- Ophthalmologist James D. Fly, MD, of Mississippi Retina Associates, performed Mississippi's first procedure for ... prweb.com Loislaw Federal District Court Opinions - NOVARTIS … - Nov 12, 2008 On August 17, 2006, Novartis ceased its promotion of Retisert. Compl. ¶ 39. In an attempt to resolve this dispute, representatives of the two companies met ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw … Uveitis; US FDA accepts NDA for Retisert implant for noninfectious... - Jan 14, 2005 2005 JAN 14 - (NewsRx.com & NewsRx.net) -- Bausch & Lomb (BOL) announced that the US Food and Drug Administration (FDA) has accepted for review the new drug ... Pay-Per-View - Drug Week - Factiva, from Dow Jones pSivida Updates Shareholders on Status of Activities. - Mar 22, 2006 ...--Three year trial results from a Bausch & Lomb study on Retisert(TM) as a treatment for ... Retisert(TM) is FDA approved for the treatment of uveitis. ... Free with registration - Business Wire - AccessMyLibrary.com Retisert implant effective for uveitis, promising for diabetic... - Oct 14, 2005 Chicago—The Retisert implant (Bausch & Lomb), a nonbiogradable device containing fluocinolone acetonide, is approved for the treatment of uveitis and seems ... Ophthalmology Times pSivida Completes Agreement to Secure Additional US$6.5m Funding - Sep 27, 2006 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... Genetic Engineering News - Genetic Engineering News (press release) PSIVIDA BROADENS PHASE III MEDIDUR TRIAL - Jun 7, 2006 These results were generated in a 198 patient US clinical trial of Retisert produced by Psivida partner, Bausch & Lomb. Retisert is a larger surgically ... Pay-Per-View - Biotech Daily - Factiva, from Dow Jones FDA Approvals: Retisert, WinRho SDF, IMx Sirolimus Assay - Apr 28, 2005 April 28, 2005 — The US Food and Drug Administration (FDA) has approved fluocinolone acetonide 0.59-mg intravitreal implant for the treatment of chronic ... Medscape pSivida Announcement: RetisertTM Drug Implant Receives Product … - Jan 29, 2007 The Retisert TM implant was approved as a single indication orphan drug by ... Retisert TM is surgically placed into the back of the eye and releases the ... Nano World News Strong results for B&L/pSivida's Retisert.(Bausch & Lomb UK Ltd.)(Brie... - Feb 27, 2006 Australian bionanotechnology firm pSivida has welcomed encouraging preliminary three-year follow-up data from Bausch & Lomb's multicenter, randomized, ... $4.95 - Pharma Marketletter - ECNext Bausch & Lomb Announces Medicare Reimbursement Terms for Retisert( … - Oct 6, 2005 ROCHESTER, NY -- Bausch & Lomb announced today that the Centers for Medicare & Medicaid Services has designated the single-indication orphan drug ... $4.95 - Business Wire - ECNext pSivida Quarterly Cashflow - March 2006 Commentary and Highlights. - Apr 28, 2006 Retisert(TM) royalties that would have otherwise been earned from launch in the ... Retisert(TM) also reduced retinal thickening involving the fovea (the ... Free with registration - Business Wire - AccessMyLibrary.com -- Commencement of BrachySil Pancreatic Cancer Dose Ranging Clinical … - Jul 31, 2008 Retisert(R) is the only FDA-approved treatment for posterior uveitis, ... Retisert data presented at the ARVO conference in 2004 and 2005 showed that at 6 ... Genetic Engineering News - Genetic Engineering News (press release) PSIVIDA LTD ADS - PSDV: Retisert(TM) Approved for Full US Medicare … - Oct 7, 2005 Medicaid Services in the United States has designated the single-indication orphan drug Retisert(TM) as eligible for Medicare pass-through payment under ... Pay-Per-View - Knobias - Factiva, from Dow Jones pSivida to Present at the Wall Street Analyst Forum - Jun 14, 2006 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... Genetic Engineering News - Genetic Engineering News (press release) Novartis to co-promote Retisert with B&L.(Novartis Ophthalmics)(Bausch... - Feb 20, 2006 Australian bio-nanotechnology company pSivida says that its Retiser product licensed to Bausch & Lomb will be co-promoted in the USA by Novartis Ophthalmics ... $4.95 - Pharma Marketletter - ECNext pSivida's CDS and Almiera initiate Ph III DME trial.(Control Delivery... - Oct 10, 2005 Retisert, the world's first intravitreal drug implant for the treatment of this condition, and has received US Food and Drug Administration fast-track ... $4.95 - Pharma Marketletter - ECNext pSivida Quarterly Cash Flow – December 31, 2007 Commentary and … - Dec 31, 2007 Cash royalties from Retisert were A$307k lower than the previous quarter due to the ... Retisert ® is the only FDA-approved treatment for posterior uveitis, ... Nano World News pSivida Release: Results From the Six-Month Interim Readout of the … - Oct 1, 2008 Retisert releases the same drug, FA, as Iluvien but at a higher dose and faster ... In a similarly sized clinical trial of Retisert in DME at 6 months, ... RedOrbit pSivida in Negotiation with Biotech Fund for A$33.7M (US$26M) for … - Nov 10, 2006 ...pSivida's lead FDA approved ophthalmic product is Retisert[TM] for the ... Medidur(TM) essentially differs from Retisert(TM) in that it is injected behind ... Free with registration - Business Wire - AccessMyLibrary.com Uveitis recurrence rate lowered, adjunctive therapy reduced with... - Aug 1, 2005 Retisert slowly releases fluocinolone acetonide during a 3-year period. ... By 2 years, the eyes implanted with the Retisert device had a recurrence rate of ... OSN SuperSite Treatment For Diabetic Macular Edema - Results From The Six-Month … - Oct 3, 2008 Retisert releases the same drug, FA, as Iluvien but at a higher dose and faster ... In a similarly sized clinical trial of Retisert in DME at 6 months, ... Medical News Today - Medical News Today (press release) pSivida Release: Results from the Six-Month Interim Readout of the … - Jan 10, 2008 Retisert releases the same drug, FA, as Iluvien but at a higher dose and faster ... In a similarly sized clinical trial of Retisert in DME at 6 months, ... Euro am Sonntag Saving Sight - Dec 7, 2005 She might not have to thanks to the implant called retisert. ... Studies show that retisert helped decrease inflammation from uveitis and improve vision. ... WOWT pSivida Provides Update on BrachySil(TM) Liver Program: Expansion of ... - May 25, 2006 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... Free with registration - Business Wire - AccessMyLibrary.com pSivida Limited: Rights Issue to Fund Late Stage Macular Edema Trials... - May 2, 2006 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks; Vitrasert(R) and Retisert(TM). ... Free with registration - Business Wire - AccessMyLibrary.com Initiation of Phase II Clinical Study of Novel Ophthalmic Product. - Sep 19, 2006 Retisert(TM) is the only FDA-approved sustained release back of the eye ... Licensed to Bausch & Lomb, Retisert(TM) is marketed in the United States and ... Free with registration - Business Wire - AccessMyLibrary.com pSivida Quarterly Cash Flow - June 30, 2007 Commentary and Highlights... - Jul 31, 2007 A product specific J-Code for Retisert([R]) went into effect on January 1, 2007, replacing the ... Retisert[R] is FDA approved for the treatment of uveitis. ... $4.95 - Business Wire - ECNext pSivida Completes Acquisition of Control Delivery Systems - Jan 4, 2006 Retisert, marketed by global US ophthalmology company Bausch & Lomb, ... Retisert was approved in October 2005 for full US CMS (Medicare) coverage at a rate ... nanotechwire.com pSivida Completes Acquisition of Control Delivery Systems - Jan 3, 2006 Retisert(TM) was approved in October 2005 for full US CMS (Medicare) ... In addition to uveitis, Bausch & Lomb has the right to use Retisert(TM) as a ... RedOrbit pSivida Announces Interim Results from the Three-Month Readout of the... - Jun 26, 2008 By comparison, Retisert(R) intravitreal implant, which releases FA at an initial ... Retisert data presented at the ARVO conference in 2004 and 2005 showed ... Genetic Engineering News - Genetic Engineering News (press release) pSivida Quarterly Cash Flow - Sept. 30, 2007 Commentary and Highlights... - Oct 31, 2007 Retisert[R] is FDA approved for the treatment of uveitis. Vitrasert[R] is FDA approved for the ... Bausch & Lomb owns the trademarks Vitrasert and Retisert. ... $4.95 - Business Wire - ECNext pSivida Announces Interim Results From The Three-Month Readout Of … - Jun 30, 2008 By comparison, Retisert® intravitreal implant, which releases FA at an ... Retisert data presented at the ARVO conference in 2004 and 2005 showed that at 6 ... Medical News Today - Medical News Today (press release) pSivida Given a 'Speculative Buy Class A' Rating by Australian... - Mar 28, 2006 The editors of Bioshares specifically focused on Retisert and Medidur, ... Retisert is licensed to Bausch and Lomb, for the treatment of chronic ... nanotechwire.com … : Copromotion-Vertrag zwischen Novartis und Bausch&Lomb für Retisert... - Feb 17, 2006 ...pSivida ist Besitzerin oder Inhaberin der exklusiven Rechte zur Nutzung des geistigen Eigentums in Bezug auf BrachySilâ„¢, Medidurâ„¢, Retisertâ„¢ und Vitrasert® ... FinanzNachrichten.de Press Release: Morning Alert for Psivida Ltd. - M2 Presswire |... - Apr 4, 2007 Retisert is FDA approved for the treatment of uveitis. Vitrasert is FDA approved for the ... Bausch & Lomb own the trademarks Vitrasert and Retisert . ... Pay-Per-View - M2 Presswire - HighBeam Research pSivida verhandelt mit Biotech-Fonds über A$33,7 Mio (USD 26 Mio) zur... - Nov 10, 2006 Retisertâ„¢ ist von der amerikanischen Arzneimittelbehörde zugelassen zur Behandlung der Uveitis. Vitrasert® ist von der FDA zugelassen zur Behandlung von ... FinanzNachrichten.de Collaborations; Deal signed to copromote intravitreal drug implant - Mar 7, 2006 Retisert is an intravitreal drug implant indicated for the treatment of ... Bausch & Lomb remains responsible for Retisert marketing and product strategy. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones pSivida Enters Licensing Negotiations with Major Global Pharma for... - Dec 26, 2006 Retisert[TM] is FDA approved for the treatment of uveitis. Vitrasert[R] is FDA approved ... Bausch & Lomb own the trademarks Vitrasert[R] and Retisert[TM]. ... Free with registration - Business Wire - AccessMyLibrary.com pSivida Completes US$2.9m Placement. - Dec 20, 2006 Retisert[TM] is FDA approved for the treatment of uveitis. Vitrasert[R] is FDA approved ... Bausch & Lomb own the trademarks Vitrasert[R] and Retisert[TM]. ... Free with registration - Business Wire - AccessMyLibrary.com pSivida Announces Transdermal Drug Delivery Program. - Nov 20, 2006 Retisert[TM] is FDA approved for the treatment of uveitis. Vitrasert[R] is FDA approved ... Bausch & Lomb own the trademarks Vitrasert[R] and Retisert[TM]. ... Free with registration - Business Wire - AccessMyLibrary.com pSivida Completes Agreement with Existing Convertible Note Holder. - Sep 15, 2006 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... Free with registration - Business Wire - AccessMyLibrary.com pSivida to Present at The Sachs Associates: London Biotech Investment... - Jun 22, 2006 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... Free with registration - Business Wire - AccessMyLibrary.com Non-Exec Director Resigns from pSivida Board. - Aug 28, 2006 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... Free with registration - Business Wire - AccessMyLibrary.com pSivida wins recognition in Germany - Sep 13, 2006 Retisert is the only FDA approved drug for this disease. Surgically implanted into the eye, Retisert is approved to release a constant amount of the drug, ... WA Business News - WA Business News (subscription) => IRW-Press: pSivida Limited: pSivida: Ergebnisse der langfristigen ... - Feb 21, 2006 ...pSivida erhält Lizenzgebühren aus dem Verkauf von Retisertâ„¢, ... Retisertâ„¢, dessen Behandlungskosten den USA von Medicare und Medicaid übernommen werden, ... FinanzNachrichten.de BIOTECH DAILY Biotech Daily - Mar 8, 2006 Psivida expects sales of Retisert for uveitis to grow dramatically with an ... Retisert requires surgical implantation in the eye, but Medidur is much ... Pay-Per-View - Biotech Daily - Factiva, from Dow Jones Stock-World - die Performance zählt. - Oct 2, 2008 Die erste Auswertung dieser PK-Studie und der Vergleich mit Retisert® von Bausch & Lomb (das ... Retisert ist dasselbe Arzneimittel wie Iluvien, nämlich FA, ... Stock World pSivida and Nordic Biotech Sign MOU for A$33.7M (US$26M) for … - Nov 13, 2006 ...pSivida's lead FDA approved ophthalmic product is Retisert(TM) for the ... Medidur(TM) essentially differs from Retisert(TM) in that it is injected behind ... Genetic Engineering News - Genetic Engineering News (press release) First Patient Implanted in pSivida European Pancreatic Cancer Study - Oct 9, 2006 Retisertâ„¢ is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the ... Bausch & Lomb owns the trademarks Vitrasert® and Retisertâ„¢. ... Nano World News pSivida to Present at UBS Global Specialty Pharmaceuticals Conference;... - Apr 21, 2006 Retisert(TM) is also co-promoted in the United States by Novartis Ophthalmic, a business unit ... Retisert(TM) is FDA approved for the treatment of uveitis. ... Genetic Engineering News - Genetic Engineering News (press release) Implant Approved To Treat Eye Condition - Aug 23, 2006 Retisert is surgically embedded in the back of the eye, and it delivers tiny amounts ... Foster said everyone who gets a Retisert will develop a cataract. ... Boston Channel.com Bausch & Lomb to Hold Investor and Media Briefing at ARVO May 3, 2005... - Apr 28, 2005 Approved by FDA, Retisert is scheduled for a mid-year US launch. The briefing will take place concurrent with the annual meeting of the Association for ... $4.95 - Business Wire - ECNext pSivida Signs $165 Million(US) Collaborative Research and Licensing … - Apr 4, 2007 Retisert([R]) is FDA approved for the treatment of uveitis. ... Bausch & Lomb own the trademarks Vitrasert([R]) and Retisert([R]). pSivida has licensed the ... Free with registration - Business Wire - AccessMyLibrary.com pSivida Corp.: Zwischenergebnisse der dreimonatigen Studie zu PK … - Jun 27, 2008 Retisert® als intravitreales Implantat setzt FA mit zunächst 0,6 µg pro Tag ... Die für Retisert auf der ARVO Konferenz 2004 und 2005 präsentierten Daten ... pressrelations.de pSivida plans new spin-out, CEO - Nov 29, 2005 Each Retisert implant sells for about $US18,000 and pSivida is expected to earn royalties of between 10 and 20 per cent for each sale. ... WA Business News - WA Business News (subscription) Uveitis treatment may aid diabetic patients. - Apr 15, 2006 ...(B & L is the exclusive licensee of pSivida and co-promotes Retisert, ... Unlike Retisert, which is surgically implanted, Medidur is injected during an ... Free with registration - Review of Optometry - AccessMyLibrary.com New eye procedure performed.(Strictly Business) - Jan 30, 2006 Prior to the development of the Retisert implant, treatment methods for uveitis included only large doses of oral steroids such as prednisone or ... Free with registration - Mississippi Business Journal - AccessMyLibrary.com WIS News 10 - Columbia, South Carolina | Health Alert: Managing... - Nov 23, 2005 The new implant is called Retisert. It sits in the eye and slowly ... Studies show Retisert helped decrease inflammation from Uveitis and improve vision. ... WIS pSivida gibt Platzierung über AUD 11,5 Mio. (USD 9 Mio.) bekannt - Feb 19, 2007 Schwere der diabetischen Retinophatie) bei DME ergeben wie Retisertâ„¢, wenn Medidurâ„¢ Fluocinolon-Acetonid nicht ebenso erfolgreich abgibt wie Retisertâ„¢, ... FinanzNachrichten.de Drei-Monats-Bericht zum Cashflow von pSivida - März 2006 - … - May 2, 2006 Retisertâ„¢ verlangsamt im Rahmen von Studien zu DME das Fortschreiten der diabetischen Retinopathie Die zusätzlichen Zwei-Jahres-Ergebnisse der beiden ... FinanzNachrichten.de IRW-News: pSivida Limited - Sep 19, 2006 Retisert ist das einzige von der FDA zugelassene nachhaltige Medikament zur ... Retisert wird in Lizenz von Bausch & Lomb in den USA vermarktet und von ... FinanzNachrichten.de pSivida und Nordic Biotech unterzeichnen MOU über A$ 33,7 Mio (US$ … - Nov 14, 2006 MedidurTM und Retisert können dasselbe Steroid (Fluocinolonacetonid oder FA) in ... Retisertâ„¢ ist von der amerikanischen Arzneimittelbehörde zugelassen zur ... FinanzNachrichten.de Enrollment Begins on Human PK Study for Medidur(TM) FA. - Aug 22, 2007 Retisert[R] is FDA approved for the treatment of uveitis. Vitrasert[R] is FDA approved ... Bausch & Lomb own the trademarks Vitrasert[R] and Retisert[R]. ... Free with registration - Business Wire - AccessMyLibrary.com Article: New eye procedure performed.(Strictly Business) - Mississippi... - Jan 30, 2006 Prior to the development of the Retisert implant, treatment methods for uveitis included only large doses of oral steroids such as prednisone or ... Pay-Per-View - Mississippi Business Journal - HighBeam Research … the single-indication orphan drug status of Bausch & Lomb's Retiser... - Jun 1, 2005 ...find Medical Marketing & Media articles. The FDA approved the single-indication orphan drug status of Bausch & Lomb's Retisert (fluocinolone acetonide... Pay-Per-View - Medical Marketing & Media - HighBeam Research pSivida: Der Medikamententräger RetisertTM erhält produktspezifischen... - Jan 31, 2007 Retisertâ„¢ wird in den Vereinigten Staaten von Bausch&Lomb vermarktet, ... Retisertâ„¢ ist eine von der FDA zugelassene Therapie für die Behandlung von Uveitis ... FinanzNachrichten.de pSivida unterzeichnet Arzneimittelfreisetzungs-Lizenzvertrag mit... - Jan 9, 2007 Retisertâ„¢ ist eine von der FDA zugelassene Therapie zur Behandlung von Uveitis. ... Bausch&Lomb ist Eigentümer der Marken Vitrasert® und Retisertâ„¢. ... FinanzNachrichten.de DSMB Again Supports Continuation of the Phase III Clinical Trial of … - Mar 24, 2008 Retisert® is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the ... Bausch & Lomb owns the trademarks Vitrasert® and Retisert®. ... Nano World News MedidurTM Programm für diabetisches Makulaödem: Aufsichtsbehörden … - Jun 7, 2006 Retisertâ„¢ ist von der amerikanischen Arzneimittelbehörde zugelassen zur Behandlung der Uveitis. Vitrasert® ist von der FDA zugelassen zur Behandlung von ... FinanzNachrichten.de pSivida Sells AION Diagnostics Subsidiary - Apr 13, 2007 Retisert ® is FDA approved for the treatment of uveitis. Vitrasert ® is FDA approved for ... Bausch & Lomb own the trademarks Vitrasert ® and Retisert ® . ... Nano World News pSivida Pancreatic Cancer Study Results Released. - Jan 28, 2008 Retisert[R] is FDA approved for the treatment of uveitis. Vitrasert[R] is FDA approved ... Bausch & Lomb owns the trademarks Vitrasert[R] and Retisert[R]. ... Free with registration - Business Wire - AccessMyLibrary.com pSivida New Clinical Trial for Drug Delivery Device in AMD - Dec 11, 2008 ...pSivida has two products approved by the Food and Drug Administration (FDA): Retisert ® to treat uveitis and Vitrasert ® for treating AIDS-related ... International Business Times pSivida Receives NASDAQ Notification Related to Minimum Bid Price - Dec 31, 2007 Retisert® is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the ... Bausch & Lomb owns the trademarks Vitrasert® and Retisert®. ... Nano World News Investor Alert for Psivida Ltd. - Apr 5, 2007 Retisert is FDA approved for the treatment of uveitis. Vitrasert is FDA approved for the ... Bausch & Lomb own the trademarks Vitrasert and Retisert . ... Free with registration - M2 Presswire - AccessMyLibrary.com pSivida schließt Vertrag mit bestehendem Convertible Note-Inhaber ab - Sep 15, 2006 Retisertâ„¢ ist von der amerikanischen Arzneimittelbehörde zugelassen zur Behandlung der Uveitis. Vitrasert® ist von der FDA zugelassen zur Behandlung von ... FinanzNachrichten.de pSivida Announces pSiNutria Business sold to Intrinsiq Materials - Jan 23, 2008 Retisert® is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the ... Bausch & Lomb owns the trademarks Vitrasert® and Retisert®. ... Nanowerk LLC pSivida Provides Additional Information on CDS Revenues, CDS … - Oct 4, 2005 Bausch & Lomb's Retisert(TM) is the world's first intravitreal drug implant for the treatment of this condition that affects an estimated 175000 people in ... Nano World News pSivida Announces Closing of First Tranche of Previously Reported … - Jul 6, 2007 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... Genetic Engineering News - Genetic Engineering News (press release) AION Diagnostics Announces BioSilicon(TM) Breakthrough; Janney … - Jun 8, 2006 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... Free with registration - Business Wire - AccessMyLibrary.com pSivida Completes Recruitment of European Pancreatic Cancer Study … - Aug 13, 2007 Retisert[R] is FDA approved for the treatment of uveitis. Vitrasert[R] is FDA approved ... Bausch & Lomb owns the trademarks Vitrasert[R] and Retisert[R]. ... Free with registration - Business Wire - AccessMyLibrary.com pSivida's BrachySilâ„¢ Pancreatic Program: Regulatory Approval for … - May 30, 2006 Retisert(TM) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(TM). ... Nano World News DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM... - Oct 17, 2007 Retisert(R) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(R). ... Free with registration - PR Newswire - AccessMyLibrary.com pSivida To Acquire Control Delivery Systems - Creates one of the... - Oct 3, 2005 Combined company's marketed products and lead product candidates: Marketed Retisert for Uveitis (CDS) An intravitreal drug implant marketed by Bausch & Lomb ... nanotechwire.com Alimera Sciences' Medidur(TM) Trial Exceeds 500 Patient Mark in Phase... - Apr 23, 2007 Retisert(R) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved ... Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(R). ... Free with registration - PR Newswire - AccessMyLibrary.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |